CSIMarket
 


Zogenix Inc   (ZGNX)
Other Ticker:  
 

Cumulative Zogenix Inc 's Total Debt to Equity for Trailing Twelve Months Period

ZGNX's Total Debt to Equity for Trailing Twelve Months Period and Total Debt, Equity growth


Select the Comparisons : Select the Ratio:

ZGNX Total Debt to Equity for Trailing Twelve Months Period

(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Sep 30 2020)
III. Quarter
Y / Y Equity Growth -57.6 % -44.64 % -39.43 % 31.1 % 68.44 %
Y / Y Total Debt Growth 23.61 % - - - -
Total Debt to Equity for Trailing Twelve Months Period 0.62 0.47 0.3 0.17 0.08
Total Ranking # 2359 # 1761 # 1418 # 1072 #
Seq. Equity Growth -20.21 % -17.8 % -15.07 % -23.88 % 4.18 %
Seq. Total Debt Growth 1.47 % 1.46 % 1.44 % 18.36 % -


Total Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2021
On the trailing twelve months basis Due to net new borrowings of 1.47%, Total Debt to Equity for Trailing Twelve Months Period improved to 0.62, a new company high.
Total Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 224 other companies have achieved lower Total Debt to Equity for Trailing Twelve Months Period than Zogenix Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Debt to Equity Ratio?
ZGNX Charts and Quotes
Total Debt to Equity ZGNX in the most recent quarter
Total Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 225
Sector # 521
S&P 500 # 2720


Total Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
0.62 0.14 0.02
(Dec 31 2021)  




Companies with similar average Total Debt to Equity for Trailing Twelve Months Period for 12 months ending Dec 31 2021, within Major Pharmaceutical Preparations Industry Total Debt to Equity for Trailing Twelve Months Period
Zoetis Inc   1.66 
Avid Bioservices Inc   1.60 
Precigen Inc   1.55 
Jazz Pharmaceuticals Plc  1.53 
Harmony Biosciences Holdings inc   1.43 
Maravai Lifesciences Holdings Inc   1.41 
Sarepta Therapeutics Inc   1.41 
Humanigen Inc  1.40 
Liminal Biosciences Inc   1.34 
Collegium Pharmaceutical Inc   1.34 
Revance Therapeutics Inc   1.26 
Insmed Inc  1.25 
Amicus Therapeutics inc   1.24 
Jaguar Health inc   1.23 
Evoke Pharma Inc   1.20 
Avadel Pharmaceuticals Plc  1.14 
Amag Pharmaceuticals inc   1.13 
Viatris Inc   1.13 
Bristol myers Squibb Company  1.12 
Prestige Consumer Healthcare Inc   1.10 
Athenex Inc   1.09 
Kala Bio inc   1.03 
Rockwell Medical inc   1.02 
Obseva Sa  1.00 
Mylan N v   0.98 
Catalent Inc   0.98 
Merck and Co Inc   0.92 
Pacira Biosciences inc   0.92 
Verrica Pharmaceuticals Inc   0.91 
Takeda Pharmaceutical Company Limited  0.90 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com